Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARγ activation

Experimental Dermatology

Volumn 19, Issue 9, 2010, Pages 813-820

  Mastrofrancesco, Arianna ^a   Ottaviani, Monica ^a   Aspite, Nicaela ^a   Cardinali, Giorgia ^a   Izzo, Enzo ^a   Graupe, Klaus ^b   Zouboulis, Christos C ^c   Camera, Emanuela ^a   Picardo, Mauro ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b GCD   (Germany)

^c DESSAU MEDICAL CENTER   (Germany)

Author keywords

Azelaic acid; Inflammatory cytokines; PPAR ; Rosacea; UV

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AZELAIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MOLECULAR MECHANICS; NEUROMODULATION; NEWBORN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; ULTRAVIOLET B RADIATION;

ACNE VULGARIS; CELLS, CULTURED; CYTOKINES; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HUMANS; KERATINOCYTES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; ROSACEA; TRANSCRIPTION, GENETIC; ULTRAVIOLET RAYS;

EID: 77955743948     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01107.x     Document Type: Article

References (46)

1. Nazzarro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G. Beneficial effect of 15% azelaic acid cream in acne vulgaris. Br J Dermatol 1983, 109:45-48.
2. Gollnick H, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology 2003, 206:29-36.
3. Kurokawa I, Danby F W, Ju Q. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009, 18:821-832.
4. Detmar M, Mayer-da-Silva A, Stadler R, Orfanos C E. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J Invest Dermatol 1989, 93:70-74.
5. Holland K T, Bojard R A, Cunliffe W J. The interaction of azelaic acid with Propionibacterium acnes. J Invest Dermatol 1989, 92:446.
6. Bojard R A, Holland K T, Cunliffe W J. The in-vitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37. J Antimicrob Chemother 1991, 28:843-853.
7. Thiboutot D. Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol 2008, 7:13-16.
8. Gupta A K, Gover M D. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol 2007, 46:533-538.
9. Gollink H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Expert Opin Pharmacother 2008, 9:2699-2706.
10. Liu R H, Smith M K, Basta S A, Farmer E R. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol 2006, 142:1047-1052.
11. Powell F C. Clinical practice. Rosacea. N Engl J Med 2005, 352:793-803.
12. Smith J R, Lanier V B, Braziel R M, Falkenhagen K M, White C, Rosenbaum J T. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 2007, 91:226-229.
13. Fimmel S, Abdel-Naser M B, Kutzner H, Kligman A M, Zouboulis C C. New aspects of the pathogenesis of rosacea. Drug Discov Today Dis Mech 2008, 5:103-111.
14. Murphy G M. Ultraviolet light and rosacea. Cutis 2004, 74:32-34.
15. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated disease. Arch Dermatol Res 1991, 283:162-166.
16. Passi S, Picardo M, De Luca C, Breathnach A S, Nazzarro-Porro M. Scavenging activity of azelaic acid on hydroxyl radicals "in vitro" Free Radic Res Commun 1991, 11:329-339.
17. Passi S, Picardo M, Zompetta C, De Luca C, Breathnach A S, Nazzarro-Porro M. The oxyradical-scavenging activity of azelaic acid in biological system" Free Radic Res Commun 1991, 15:17-28.
18. Jones D. Reactive oxygen species and rosacea. Cutis 2004, 74(Suppl. 17-20):32-34.
19. Arican O, Kurutas E B, Sasmaz S. Oxidative stress in patients with acne vulgaris. Mediators Inflamm 2005, 6:380-384.
20. El-Akawi Z, Abdel-Latif N, Abdul-Razzak K. Does the plasma level of vitamins A and E affect acne condition? Clin Exp Dermatol 2006, 31:430-434.
21. Wolf J E, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006, 77:3-11.
22. Köck A, Schwarz T, Kirnbauer R. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 1990, 172:1609-1614.
23. Kirnbauer R, Köck A, Neuner P. Regulation of epidermal cell interleukin-6 production by UV light and corticosteroids. J Invest Dermatol 1991, 96:484-489.
24. Mayuzumi N, Ikeda S, Kawada H, Fan P S, Ogawa H. Effects of ultraviolet B irradiation, proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1. Br J Dermatol 2005, 152:697-701.
25. Cheng H M, Hsiang C Y, Chen G W. Inhibition of lipopolysaccharide-induced interleukin-1beta and tumor necrosis factor-alpha production by menthone through nuclear factor-kappaB signaling pathway in HaCaT cells. Chin J Physiol 2008, 51:160-166.
26. Lewis D A, Spandau D F. UVB activation of NF-κB in normal human keratinocytes occurs via a unique mechanism. Arch Dermatol Res 2007, 299:93-101.
27. Sertznig P, Seifert M, Tilgen W. Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin. Importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 2008, 9:15-31.
28. Nazzarro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978, 71:205-208.
29. Su C G, Wen X, Bailey S T. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999, 104:383-389.
30. Ellis C N, Varani J, Fisher G J. Troglitazone improves psoriasis and normalizes models of proliferative skin disease. Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000, 136:609-616.
31. Pincelli C, Sevignani C, Manfredini R. Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. J Invest Dermatol 1994, 103:13-18.
32. Rocchi S, Picard F, Vamecq J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001, 8:737-747.
33. Lewis D A, Spandau D F. UVB-induced activation of NF-κB is regulated by IG-1R and dependent on p38 MAPK. J Invest Dermatol 2008, 128:1022-1029.
34. Ricote M, Li A C, Willson T M, Kelly C J, Glass C K. The peroxisome proliferators-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
35. Delerive P, Fruchart J C, Staels B. Peroxisome proliferators-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459.
36. Chung S W, Kang B Y, Kim S H, Cho D, Trinchieri G, Kim T S. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interaction between PPARγ and NF-κB. J Biol Chem 2000, 276:32681-32687.
37. Simon M M, Aragane Y, Schwarz A, Luger T A, Schwarz T. UVB light induces nuclear factor κB (NFκB) activity independently from chromosomal DNA damage in cell-free cytosolic extracts. J Invest Dermatol 1994, 102:422-427.
38. Adhami V M, Afaq F, Ahmad N. Suppression of ultraviolet B exposure-mediated activation of NF-kappa-B in normal human keratinocytes by resveratrol. Neoplasia 2003, 5:74-82.
39. Peus D, Vasa R A, Beyerle A, Meves A, Krautmacher C, Pittelkow M R. UVB activatesERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol 1999, 112:751-756.
40. Mantena S K, Katiyar S K. Grape seed proanthocyanidins inhibits UV-radiation-induced oxidative stress and activation of MAPK and NF-κB signaling in human epidermal keratinocytes. Free Radic Biol Med 2006, 40:1603-1614.
41. Kim J K, Kim Y, Na K M, Surh Y J, Kim T Y. [6]-Gingerol prevents UVB-induced ROS production and Cox-2 expression in vitro and in vivo. Free Radic Res 2007, 41:603-614.
42. Wahli W, Braissant O, Desvergne B. Peroxisome proliferators activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 1995, 2:261-266.
43. Rivier M, Safonova I, Lebrun P, Griffiths C E, Ailhaud G, Michel S. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998, 111:1116-1121.
44. Pascual G, Fong A L, Ogawa S. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
45. Jiang C, Ting A T, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
46. Mao-Qiang M, Fowler A J, Schmuth M. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 2004, 123:305-312.